Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin hemodynamic impact in heart failure (EMBRACE-HF)
NCT03030222Phase 4Completed
- Sponsor
- Saint Luke's Health System
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure (HF), sponsored by Saint Luke's Health System. Started Jul 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03030222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030222.